Retrospective Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Dec 27, 2023; 15(12): 2783-2791
Published online Dec 27, 2023. doi: 10.4240/wjgs.v15.i12.2783
Percutaneous microwave ablation and transcatheter arterial chemoembolization for serum tumor markers and prognostics of middle-late primary hepatic carcinoma
Zhi-Peng Lin, Da-Bei Huang, Xu-Gong Zou, Yuan Chen, Xiao-Qun Li, Jian Zhang
Zhi-Peng Lin, Da-Bei Huang, Xu-Gong Zou, Yuan Chen, Xiao-Qun Li, Jian Zhang, Department of Interventional Medicine, Zhongshan People’s Hospital, Zhongshan 528400, Guangdong Province, China
Author contributions: Lin ZP performed the research and wrote the paper; Huang DB designed the research; Zou XG contributed to the analysis; Chen Y and Li XQ organized the materials; Zhang Jie guided and supervised the research.
Institutional review board statement: The study was reviewed and approved by the Zhongshan People’s Hospital Institutional Review Board (Approval No. 2023-038).
Informed consent statement: This is a retrospective study article, which selected anonymous patients from the hospital system. The patient's identity information was not disclosed and will not cause any harm to the patient. An application for exemption from informed consent has been made to the ethics committee.
Conflict-of-interest statement: The authors declare no conflicts of interest for this article.
Data sharing statement: Clinical data used in this study can be obtained from the corresponding author.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jian Zhang, MD, Professor, Department of Interventional Medicine, Zhongshan People’s Hospital, No. 2 Sun Wen East Road, Zhongshan 528400, Guangdong Province, China. wy18988583838@163.com
Received: October 26, 2023
Peer-review started: October 26, 2023
First decision: November 8, 2023
Revised: November 17, 2023
Accepted: December 4, 2023
Article in press: December 4, 2023
Published online: December 27, 2023
Processing time: 62 Days and 9.6 Hours
Core Tip

Core Tip: Middle- and late-stage primary hepatic carcinoma (PHC) has reached a phase of comprehensive treatment. Compared to single interventional therapy, transcatheter arterial chemoembolization (TACE) plus percutaneous microwave coagulation therapy (PMCT) can effectively improve prognosis and prolong patient survival. This study reveals that TACE + PMCT in the management of patients with middle-late PHC enhances tumor marker levels and prolongs survival time. Furthermore, we identify tumor diameter, tumor number, and treatment method as pivotal factors influencing prognosis.